CAROTID INTIMA-MEDIA THICKNESS IS INCREASED IN MEXICAN-MESTIZO PATIENTS WITH RHEUMATOID ARTHRITIS: A CASE-CONTROL STUDY

D.A. Galarza-Delgado1, J.R. Azpiroz-Lopez2, I.J. Colunga-Pedraza1, A.H. Guillen-Lozoya1, J.A. Davila-Jimenez2, E.E. Abundis-Marquez2, J.A. Cardenas-De la Garza1, R. Vera-Pineda1, A. Valdivinos-Baruelos1, R.E. Ramos-Cazares1, F.J. Torres-Quintana1, R.I. Avizul1, A. Martinez-Moreno1. 1Rheumatology; 2Cardiology, Hospital Universitario “Dr José E. Gonzalez”, UANL, Monterrey, Mexico

Background: Patients with rheumatoid arthritis (RA) have a significantly increased risk for cardiovascular (CV) morbidity and mortality when compared to general population. Traditional risk factors do not explain the increased CV risk, which appears to be linked to chronic inflammation.1 The leading cause of death in RA patients is atherosclerotic cardiovascular disease (ASCVD).2 Carotid artery evaluation by ultrasound is a useful tool for the detection of subclinical atherosclerosis. The presence of increased carotid intima-media thickness (CIMT) significantly raises the risk of ASCVD, mainly stroke and myocardial infarction.3

Objectives: To compare CIMT between Mexican-mestizo RA-patients and matched controls.

Methods: Design: observational, cross-sectional, case-control study. Patients 40 to 75 years old who fulfilled the 2010 ACR/EULAR and/or the 1987 ACR classification criteria for RA were consecutively enrolled. Patients with previous ASCVD or any other rheumatic disease were excluded. Carotid artery wall hypertrophy (CAWH) was defined as a CIMT >0.9 and<1.2 mm whereas carotid plaque (CP) was defined as a CIMT >1.2 mm or ≥50% focal increase of CIMT compared to the surrounding wall.

Results: A total of 100 RA-patients and 49 matched control subjects were included in the final analysis. Their characteristics are shown in Figure 1. RA-patients had a median disease duration of 10.3 years and a median DAS28-ESR of 3.2. Regarding carotid ultrasound findings, there was a significant difference in the surrounding wall.

Conclusions: There was significantly increased CIMT and presence of CAWH in RA-patients compared to matched controls. These findings might be major contributors to the increased CV morbidity and mortality of RA-patients. Further research is needed to determine the relationship between RA-specific factors such as disease duration and activity and the presence and magnitude of carotid ultrasound abnormalities.

REFERENCES:

Acknowledgements: None

Disclosure of Interest: None declared


METABOLIC SYNDROME AND ITS COMPONENTS AMONG HISPANIC RA PATIENTS: A CASE CONTROL STUDY

D.A. Galarza-Delgado1, J.R. Azpiroz-Lopez2, I.J. Colunga-Pedraza1, A.H. Guillen-Lozoya1, E.E. Abundis-Marquez2, J.A. Dávila-Jiménez3. 1Rheumatology; 2Cardiology, Hospital Universitario “Dr José E. Gonzalez”, UANL, Monterrey, Mexico

Background: Metabolic syndrome (MetS) comprises a group of risk factors for type 2 diabetes and cardiovascular diseases. MetS is responsible for a three-fold increase in the risk of atherosclerotic cardiovascular diseases (ASCVD) and increased mortality compared to general population.1 The frequency of MetS in RA patients is 14% to 56%. However, although many studies have reported a higher prevalence of MetS among RA patients, a number of studies have reported a higher prevalence of MetS in healthy controls.2 Despite the importance of detection of MetS and its role in RA patients, information is scarce.

Objectives: To compare the prevalence of MetS among Mexican-mestizo RA-patients and matched controls.

Methods: Design: observational, cross-sectional, case-control study. Patients of 40 to 75 years old who fulfilled the 2010 ACR/EULAR and/or the 1987 ACR classification criteria for RA were consecutively enrolled. Patients with any other rheumatic disease were excluded. Our study used ATP III Criteria (Abdominal obesity: Men>102 cm Women>88 cm; Triglyceride level >150 mg/dL; HDL<40 mg/dL for men<50 mg/dL for women; Blood pressure >130/85 mmHg; Fasting glucose >100 mg/dL) to classify patients with MetS.

Results: There were no differences in any independent variable of these patients. However there was a higher prevalence of high blood pressure in controls than RA patients (See Table 1).

Conclusions: There is no difference in the diagnosis of MetS in RA patients than control population. However, the role of the diagnosis of MetS in RA patients represents an important task in the management of the disease in order to reduce its high cardiovascular risk.

REFERENCES:

Acknowledgements: None

Disclosure of Interest: None declared